Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Phase II Chemotherapy with Cyclic Daily Anguidine for Gastrointestinal Tract Adenocarcinoma

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Treatment Closed no age specified SEG-77GI0202
SEG-77GI221

Objectives

I.  Assess activity of anguidine on treated and untreated adenocarcinoma of 
the gastrointestinal tract (stomach, colon, rectum, and pancreas) using a 
cyclic daily schedule.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with histologically proven, 
measurable adenocarcinoma of the stomach, colon, rectum, or pancreas.  
Patients must have an expected survival of more than 6 weeks, normal 
hematological status, bone marrow and liver function, and a Karnofsky status 
greater than 50%.  Fifty percent of the protocol population will be previously 
untreated patients.

Expected Enrollment

Protocol closed 07/80.

Outline

Nonrandomized study.
Regimen A:  Single-agent Chemotherapy.  Anguidine, ANG, NSC-141537.

Published Results

DeSimone PA, Greco FA, Lessner HF, et al.: Phase II evaluation of anguidine (NSC 141537) in 5-day courses in colorectal adenocarcinoma. A Southeastern Cancer Study Group Trial. Am J Clin Oncol 9 (3): 187-8, 1986.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Southeastern Cancer Study Group

George A. Omura, MD, Protocol chair
Ph: 205-444-4617

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.